FY2026 EPS Estimates for MediciNova Lowered by HC Wainwright

MediciNova, Inc. (NASDAQ:MNOV) – Equities research analysts at HC Wainwright decreased their FY2026 earnings per share estimates for MediciNova in a note issued to investors on Friday, August 14th. HC Wainwright analyst L. Egana-Gorrono now forecasts that the biopharmaceutical company will earn ($0.28) per share for the year, down from their previous estimate of ($0.26). The consensus estimate for MediciNova’s current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for MediciNova’s Q4 2026 earnings at ($0.11) EPS and FY2027 earnings at ($0.45) EPS.

MediciNova (NASDAQ:MNOV) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. MediciNova had a negative return on equity of 26.51% and a negative net margin of 1,168.70%.The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.07 million.

MNOV has been the subject of a number of other research reports. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of MediciNova in a research note on Monday, May 4th. Weiss Ratings downgraded MediciNova from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, MediciNova currently has an average rating of “Moderate Buy” and an average target price of $8.33.

MediciNova Stock Up 0.8%

Shares of NASDAQ MNOV opened at $1.32 on Tuesday. The company has a market cap of $64.97 million, a PE ratio of -6.29 and a beta of 0.63. MediciNova has a twelve month low of $1.17 and a twelve month high of $1.96. The business’s 50 day moving average price is $1.34 and its two-hundred day moving average price is $1.41.

Hedge Funds Weigh In On MediciNova

A number of hedge funds and other institutional investors have recently made changes to their positions in MNOV. StoneX Group Inc. acquired a new position in MediciNova in the fourth quarter valued at $25,000. Goldman Sachs Group Inc. acquired a new position in MediciNova during the 4th quarter worth approximately $35,000. Citadel Advisors LLC acquired a new stake in MediciNova in the 3rd quarter valued at $92,000. Bank of New York Mellon Corp bought a new position in shares of MediciNova in the second quarter valued at $103,000. Finally, Jane Street Group LLC bought a new stake in MediciNova during the 4th quarter worth approximately $214,000. 9.90% of the stock is owned by institutional investors and hedge funds.

MediciNova Company Profile

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.